Literature DB >> 7743354

Posttraumatic multiple organ failure--a report on clinical and autopsy findings.

H C Pape1, D Remmers, W Kleemann, J A Goris, G Regel, H Tscherne.   

Abstract

In a retrospective analysis, clinical data and histological specimens were obtained from patients (n = 59) who died of severe injury. Three groups with comparable injury severity were differentiated according to the time of death. In group A (death, within 24 h) (n = 15) despite multiple injuries, patients almost always died from brain injury. Pulmonary failure was the leading cause of death in group B (death, days 2-7) (n = 16). The majority of group C patients (death, > 7 days) (n = 28) died of multiple organ failure. Organ weights at autopsy were all pathologically high but did not show an association with the amount of intravenous volume infused during intensive care. Organ histology revealed signs of interstitial edema and infiltration of polymorphonuclear leukocytes in group B patients especially in the lung, and in all groups to a lower degree in liver and kidney. The distribution of interstitial edema and cell necrosis appeared to be organ-specific. Our data confirm the presence of a generalized inflammatory reaction in patients with severe trauma. The pattern of organ failure, in addition to known pathogenetic changes (mediators, endotoxemia, etc.), appears to be influenced by organ structure and perfusion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7743354     DOI: 10.1097/00024382-199409000-00012

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  2 in total

1.  Multiple organ failure (MOF) after severe trauma--a sheep model.

Authors:  H C Pape; M Grotz; D Remmers; A Dwenger; R Vaske; D Wisner; H Tscherne
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

2.  Trauma care in Germany: an inclusive system.

Authors:  Johannes A Sturm; Hans-Christoph Pape; Thomas Dienstknecht
Journal:  Clin Orthop Relat Res       Date:  2013-09       Impact factor: 4.176

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.